MCM
FLNA

Moore Capital Management’s Filana Therapeutics FLNA Stock Holding History

Moore Capital Management’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-7,143
Closed -$87K – 385
2015
Q2 		$87K Buy
+7,143
New +$97.9K ﹤0.01% 404

Other funds holding FLNA

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Moore Capital Management's FLNA Position: Q3 2015 in Review

Moore Capital Management sold out of Filana Therapeutics (FLNA) in Q3 2015, closing a stake of 7,143 shares — an estimated $87K sold.

Moore Capital Management first reported a position in FLNA in Q2 2015 and held it in 1 quarter. The position peaked at $87K in Q2 2015. 49 funds tracked by Wall St. Rank hold FLNA as of Q3 2015.

  • Moore Capital Management reported no remaining Filana Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Moore Capital Management sold 7,143 Filana Therapeutics shares in Q3 2015, an estimated $87K.
  • Moore Capital Management first reported a position in Filana Therapeutics in Q2 2015 and held it in 1 quarter.
  • Moore Capital Management's Filana Therapeutics position peaked at $87K in Q2 2015.
  • 49 funds tracked by Wall St. Rank held Filana Therapeutics as of Q3 2015.

Based on Moore Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.